BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today announced that it has completed the follow-up component of a Phase 1 multiple ascending dose (MAD) study with NGD-4715, an MCH-1 receptor antagonist being investigated for the treatment of obesity.
